statistiche ricercatore

statistiche per Andreotti, Felicita

Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1215
NA - Nord America 1143
AS - Asia 528
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 8
AF - Africa 3
Totale 2906
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1134
CN - Cina 450
DE - Germania 382
UA - Ucraina 209
SE - Svezia 188
IT - Italia 178
GB - Regno Unito 90
FR - Francia 75
FI - Finlandia 44
TR - Turchia 29
IN - India 15
RU - Federazione Russa 10
IR - Iran 9
EU - Europa 8
IE - Irlanda 8
JP - Giappone 7
VN - Vietnam 6
BR - Brasile 5
PL - Polonia 5
AT - Austria 4
CA - Canada 4
DO - Repubblica Dominicana 4
NL - Olanda 4
CZ - Repubblica Ceca 3
KR - Corea 3
RO - Romania 3
BE - Belgio 2
CH - Svizzera 2
CL - Cile 2
HK - Hong Kong 2
PT - Portogallo 2
SG - Singapore 2
TW - Taiwan 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BZ - Belize 1
DK - Danimarca 1
GR - Grecia 1
IQ - Iraq 1
MK - Macedonia 1
MU - Mauritius 1
NO - Norvegia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 2906
Salva come PNG Salva come JPEG
Città #
San Mateo 159
Hangzhou 115
Wilmington 112
Jacksonville 105
Nanjing 98
Cattolica 93
Boston 84
Beijing 78
Ann Arbor 53
Menlo Park 52
Lancaster 50
Redwood City 37
Dearborn 35
Nanchang 34
Woodbridge 34
Fairfield 33
Izmir 27
Munich 26
Houston 25
Seattle 21
Milan 20
Mountain View 18
Nürnberg 18
Ashburn 17
Redmond 17
Norwalk 16
Shenyang 15
Hebei 12
Kunming 12
Zhengzhou 12
Augusta 10
Jiaxing 10
Tianjin 10
Changsha 9
Detroit 8
Leawood 8
Shanghai 8
University Park 8
Andover 7
Guangzhou 7
Rome 7
Zhongxin 7
Hanoi 6
Cambridge 4
Florence 4
Hefei 4
Kish 4
Santo Domingo 4
Vienna 4
Fremont 3
Maastricht 3
Ningbo 3
Southend 3
Taizhou 3
Toronto 3
Ardabil 2
Bologna 2
Clearwater 2
Fort Worth 2
Gurgaon 2
Hamburg 2
Lanzhou 2
Legnano 2
Los Angeles 2
Millbury 2
Monmouth Junction 2
Muizenberg 2
New York 2
Sacramento 2
Saint Louis 2
San Diego 2
Simi Valley 2
Singapore 2
Villeurbanne 2
Wuhan 2
Ankara 1
Antalya 1
Arbil 1
Atlanta 1
Atri 1
Auburn Hills 1
Bangkok 1
Baotou 1
Belize City 1
Bloomfield 1
Boca Raton 1
Changchun 1
Chengdu 1
Cullompton 1
Dallas 1
Dubai 1
Dublin 1
Duncan 1
Federal 1
Fuzhou 1
Geesthacht 1
Geneve 1
Gent 1
Greensboro 1
Hampstead 1
Totale 1640
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 149
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 118
Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women 111
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function 80
Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients 78
Intraventricular conduction abnormalities in young patients with type 1 diabetes mellitus 74
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology 62
IGF-1 and microvascular complications of diabetes: alternative interpretation of recently published data 58
Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction 57
Mechanisms, pathophysiology, and management of obesity 57
Body fat and cardiovascular risk: understanding the obesity paradox 56
Bedside monitoring of antiplatelet therapy for coronary stenting 56
A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. 52
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials 50
Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies 49
Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS) 49
Mechanisms, Pathophysiology, and Management of Obesity 47
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 47
Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology 46
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis 46
Testosterone, tissue factor inhibition and vascular aging 45
Leading avoidable cause of premature deaths worldwide: case for obesity 44
The unstable plaque: a broken balance 42
Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials 41
Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials 40
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 40
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 39
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome 39
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper 38
Role of PAPP-A in atherothrombosis: messages to take home 38
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor 37
Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism 36
Bedside monitoring of antiplatelet therapy for coronary stenting 36
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management 34
Hemoglobin levels, nitric oxide bioavailability and cardiovascular outcomes 33
Sex differences in mechanisms, presentation and management of ischaemic heart disease 32
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis 32
EuroThrombosis: annual meeting of the European Society of Cardiology Working Group on Thrombosis 31
Polycythemia, vascular function, and hemoglobin-nitric oxide reactions 30
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 30
Women and coronary disease 29
Defining the role of left atrial appendage closure in atrial fibrillation 29
Stakeholders in NOACs prescription: Authors' reply 29
Anemia contributes to cardiovascular disease through reductions in nitric oxide 29
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study 28
Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 26
Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives 25
Last word on viewpoint: Anemia contributes to cardiovascular disease through reductions in nitric oxide 24
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: A jump with a weak parachute? 24
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis 22
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 22
Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis 21
Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients 21
Impact of coronary stenting on top of medical therapy and of inclusion of periprocedural infarctions on hard composite endpoints in patients with chronic coronary syndromes: a meta-analysis of randomized controlled trials 20
Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel 19
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: A review 19
The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? 18
Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials 18
Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of STEMI 18
Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation 18
Diagnoses and outcomes in patients with suspected angina: What are they trying to tell us? 17
Fibrinogen as a marker of inflammation: a clinical view 17
Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: A systematic review and meta-analysis 16
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 16
G20210A prothrombin gene polymorphism and extent of coronary disease 15
Normothermia does not improve postoperative hemostasis nor does it reduce inflammatory activation in patients undergoing primary isolated coronary artery bypass 15
Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: A systematic review and meta-analysis 14
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy 14
The G20210A prothrombin mutation and the Physicians' Health Study 14
Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization 14
Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery 14
Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial) 14
Homocysteine and risk of cardiovascular disease 13
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS 13
Family history in first degree relatives of patients with premature cardiovascular disease 13
Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes 12
Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes 11
Homocysteine and arterial occlusive disease: a concise review 11
[Inflammatory and fibrinolytic activation after coronary artery bypass with extracorporeal circulation] 11
Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering a systematic review and meta-analysis 11
Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: Not a matter of faith 11
Ticlopidine and aspirin fail to suppress the increased platelet aggregability that follows percutaneous coronary interventions 10
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population 10
G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome 10
Aspirin and the prevention of a common disease: Colorectal cancer 9
Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry 9
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs 9
Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions 9
Sex- and gender‑specific precision medicine for chronic coronary syndromes: challenges and opportunities 9
Reversible left anterior descending artery spasm, prolonged cardiac arrest and left main thrombosis during a PTCA attempt of the circumflex artery 8
4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: A prospective study 8
Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal 8
Glycoprotein la C807T qene polymorphism and increased risk of recurrent acute coronary syndromes: A five year follow up 8
Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people 8
Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention? 8
Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease 7
Stent Thrombosis With Dual Antithrombotic Therapy in Atrial Fibrillation–ACS/PCI Trials 7
Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure 7
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial 7
Methodological education in response to the quality of COVID-19 publications 7
Totale 2982
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3025
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3025
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2016/20179 0000 00 00 0009
2017/2018353 28193130 218 1227 29212233
2018/2019342 1652267 5818 5613 2193324
2019/2020526 129111620 2835 3518 49267782
2020/2021520 6352742 6032 588 64181106
2021/2022912 7362865 5023 20162 3950192168
Totale 3025
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie-Privacy
Logo CINECA  Copyright © 2022